Kidney calculi
Drug research and approvals for kidney calculi: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 115 studies of kidney calculi are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 115
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Supine vs. Prone Mini-PCNL in ChildrenNCT07887945 · Not applicable · Fayoum University Hospital · starts Oct 5, 2026
- Comparison of Suction and Conventional Ureteral Access Sheaths in Kidney Stone SurgeryNCT07866209 · Not reported · Antalya Health Sciences University · starts Mar 18, 2026
- Direct In-Scope Suction Versus Standard Flexible UreterorenoscopyNCT07864194 · Not applicable · Hitit University · starts Jul 7, 2026
- Human Voice vs AI-Cloned Voice Audio Added to Written Consent Before Ureteroscopy or Retrograde Intrarenal Surgery…NCT07859436 · Not applicable · Aydin Adnan Menderes University · starts Sep 28, 2026
- The GranStone TrialNCT07828002 · Phase 2 / Phase 3 · Martin Blomberg Jensen · starts Oct 20, 2026
- Effect of Emergency Urinary Drainage on Subsequent PCNL Outcomes in Obstructive UrosepsisNCT07826325 · Not applicable · Beni-Suef University · starts Oct 1, 2026
- Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)NCT07776626 · Phase 1 · YolTech Therapeutics Co., Ltd · starts Aug 1, 2026
- Role of Pre-stenting Before Retrograde Intrarenal Surgery With Miniaturized Flexible UreteroscopesNCT07773090 · Not applicable · Al-Azhar University · starts Aug 19, 2026
- Long-term Safety of UAS-assisted vs Sheathless RIRS in Non-prestented PatientsNCT07767773 · Not reported · Al-Azhar University · starts Aug 16, 2026
Phase 3 12 of 16
- SilodosinAlpha-1a adrenergic receptor antagonist
- TamsulosinAdrenergic receptor alpha-1 antagonist
- NifedipineVoltage-gated L-type calcium channel blocker
- KetorolacCyclooxygenase inhibitor
- OxycodoneMu opioid receptor agonist
- HydrochlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
- AlfuzosinAdrenergic receptor alpha-1 agonist
- AcetaminophenCyclooxygenase inhibitor
- CiprofloxacinBacterial DNA gyrase inhibitor
- GentamicinBacterial 70S ribosome inhibitor
- MorphineMu opioid receptor agonist
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
Phase 2 11
- Potassium citrate
- FebuxostatXanthine dehydrogenase inhibitor
- AllopurinolXanthine dehydrogenase inhibitor
- TolterodineMuscarinic acetylcholine receptor M3 antagonist
- FexofenadineHistamine H1 receptor antagonist
- ChlorthalidoneThiazide-sensitive sodium-chloride cotransporter inhibitor
- IsoproterenolAdrenergic receptor beta agonist
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- LumasiranHydroxyacid oxidase 1 mRNA RNAi inhibitor
- Citric acid
- MPC-5971
Phase 1 or earlier 3
- KetoprofenCyclooxygenase inhibitor
- Potassium sodium hydrogen citrate
- Potassium bicarbonate
How its trials ended
485 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 64 whose ending is known, 28% met their primary endpoint, 8% missed it and 64% stopped early.
- Completed, result not reported19039%
- Ongoing12626%
- Status unknown10522%
- Stopped: other or unclear286%
- Met its primary endpoint184%
- Stopped: enrollment or feasibility82%
- Missed its primary endpoint51%
- Stopped: sponsor or business decision31%
- Stopped: funding2<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA